ForDoz Pharma announced today that it entered into an agreement with LipoMedix to manufacture its lead compound for a clinical trial. LipoMedix’s pegylated liposomal Promitil (PL-MLP) is designed for the selective delivery of the therapeutic agent to cancer-affected tissues and is suited for cancer chemoradiotherapy, according to a news release. Studies have shown PL-MLP to […]
